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Cellular immune responses are initiated by direct inter-
action of naiveTcells with professional antigen-present-
ing cells, i.e., dendritic cells. In general, this interaction
takes place in secondary lymphoid organs to which
both naive T cells and mature dendritic cells preferen-
tially home. This physiologic scenario di¡ers substan-
tially, however, from therapeutic dendritic-cell-based
vaccinations used to treat human cancer. In fact, only a
small fraction of intradermally injected dendritic cells
migrate to the draining lymph node and the majority
of cells remain at the site of inoculation. These sites
are characterized by a distinct oligoclonal T cell in¢l-
trate comprising both L-Selectinþ/CD45RAþ and
L-Selectinþ/CD45RA cells. Blood vessels expressing
peripheral lymph node addressin represent possible en-
try channels for such naive and central memoryTcells,
the former probably attracted by dendritic cell-CK1
produced by the injected dendritic cells. In situ staining
with multimeric peptide/major histocompatibility
complex class I complexes revealed that in¢ltrating
T cells speci¢cally recognize peptide epitopes presen-
ted by the injected dendritic cells. Thus, the fraction of
dendritic cells not migrating to secondary lymphatic
tissue after therapeutic inoculation nevertheless
seem to be involved in a speci¢c immune modulation.
Key words: DC vaccination/melanoma/MHC class I multi-
mers/peptide. J Invest Dermatol 119:1443 ^1448, 2002
M
any tumors, e.g., melanoma, are known to be
immunogeneic; thus, much e¡ort has been
spent on creating tumor therapies that enhance
and/or modulate antitumor immune responses.
One such approach is the use of dendritic cells
(DC) to present tumor-associated antigens and thereby generate
tumor-speci¢c immunity. DC were chosen as they are potent in-
itiators and modulators of cellular immune responses. Their phy-
siologic role is that of a sentinel (Banchereau and Steinman, 1998):
in their immature state DC capture antigen in peripheral tissues
and subsequently migrate to lymphoid organs where, after ma-
turation, they present the processed antigens in the context of
major histocompatibility complex (MHC) molecules together
with the necessary costimulating signals. This allows recruitment,
priming, and activation of antigen-speci¢c lymphocytes
(reviewed in Banchereau et al, 2000).
The therapeutic setting, however, does not re£ect the physiolo-
gic situation, as DC are generated, pulsed with antigen, and ma-
tured in vitro prior to injection into the patient. In murine models
it became obvious that intradermal inoculation of mature DC is
superior to intravenous injection with respect to migration to the
draining lymph node (Eggert et al, 1999). Nevertheless, only a
small percentage of inoculated DC indeed reach the secondary
lymphoid tissue whereas the majority remain at the injection site
(Lappin et al, 1999). In this regard, the frequent clinical observa-
tion of in£ammatory reactions at the injection sites suggests that
DC that fail to reach secondary lymphoid tissue nevertheless ex-
ert e¡ects on the immune system. Moreover, several lines of evi-
dence indicate a relevant contribution of DC to induction and
maintenance of secondary lymphatic tissue (reviewed in Girard
and Springer, 1995). This prompted us to characterize the inocula-
tion site of DC in more detail.
Taking advantage of the recently developed technique to track
antigen-speci¢c T cells in situ in conjunction with reverse tran-
scription polymerase chain reaction (RT-PCR)/denaturing gradi-
ent gel electrophoresis (DGGE) clonotype mapping we were able
to demonstrate the accrual of clonally expanded T cells speci¢c
for the presented antigens to the intradermal inoculation site of
the DC (thor Straten et al, 1998; Haanen et al, 2000; Skinner et al,
2000; Andersen et al, 2001b). Further analysis revealed that a por-
tion of theseTcells possessed a phenotype characteristic for either
naive or central memory cells; thus, antigen-pulsed mature DC
seem to attract both antigen-experienced as well as naive T cells
to the compartment where they have been placed.
PATIENTS AND METHODS
Patients, therapeutic procedures, and sample selection The
samples for the experiments were collected from six males, ¢ve
su¡ering from stage IV and the other from stage III melanoma,
receiving DC-based vaccination and participating in phase I
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studies. The patients provided informed consent to participate in
this experimental procedure and to donate skin biopsies for
immunologic monitoring. The patients’ HLA types, which were
relevant for the vaccination, are given inTable I.
The detailed vaccination protocol, results of the routine
immune monitoring, and the clinical course have been recently
reported (Andersen et al, 2001a). Cells used for vaccination were
highly enriched in mature DC with 490% possessing the
phenotype HLA-DRþ þ þ , CD86þ þ þ , CD40þ, CD25þ,
CD14, and480% expressing CD83. Peptides used to pulse the
DC were synthesized at GMP quality (Clinalfa, Laeufel¢ngen,
Switzerland), whereas the oncolysates were prepared as des-
cribed previously (Grabbe et al, 1991). The peptides used for
the individual vaccinations are given in Table I. These
peptides included the HLA-A2-restricted MAGE-3271^279
(FLWGPRALV) epitope (Valmori et al, 1997), a modi¢ed HLA-
A2-restricted gp100209^217 epitope (IMDQVPFSV) (Pass et al,
1998), a modi¢ed HLA-A2-restricted MART-126^35 peptide
analog (ELAGIGILTV) (Valmori et al, 1998), the HLA-A2-
restricted tyrosinase214^222 peptide (FLLRWEQEI) (Reynolds
et al, 1998), the HLA-A2-restricted Survivin 1M2 peptide
(LMLGEFLKL) (Andersen et al, 2001b), the HLA-A3-restricted
gp10017^25 epitope (ALLAVGATK) (Skipper et al, 1996), the
HLA-B44-restricted tyrosinase192^200 epitope (SEIWRDIDF),
and the B44-restricted MAGE-3167^175 epitope (MEVDPIGHLY)
(Fleischhauer et al, 1996). Per injection site 5106 DC were
inoculated and patients received up to 30106 DC at each visit.
Each patient underwent several vaccinations. Skin biopsies were
obtained from vaccination sites after repeated vaccination either
24 or 48 h after DC inoculation. For a coherent and conclusive
presentation of the results obtained, however, the data presented
within this study apply to patient 1 unless otherwise stated and
represent comparable ¢ndings in the other patients irrespective
of the vaccination applied. An overview over the analyzed
samples and the results obtained is given inTable I; the tetramer
stainings were repeated on di¡erent sections of the samples.
Quantitative PCR We determined the relative expression of
the chemokines DC-CK1 (CCL18) and SDF-1 (CXCL12) by
real-time PCR and by the comparative DDCT method. Primers
and probe for DC-CK1 and SDF-1 were designed with the
Primer Express software (Applied Biosystems) and are as
follows: 50 -CCT CCT GGC AGA TTC CAC AA-30 (forward
primer), 50 -TGA TGT ATT TCT GGA CCC ACT TCT T-30
(reverse primer), 50 -FAM-CCA AGC CAG GTG TCA TCC
TCC TAA CCA-TAMRA-30 (probe) for DC-CK1, and 50 -CCA
GAG CCA ACG TCA AGC AT-30 (forward primer), 50 -TGC
ACA CTT GTC TGT TGT TGT TCT T-30 (reverse primer), 50 -
FAM-TGC CCT TCA GAT TGTAGC CCG GCT-TAMRA-30
(probe) for SDF-1. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Applied Biosystems) served as endogenous control.
The e⁄ciencies of the PCRs were determined as 92% for
DC-CK1, 90.25% for SDF-1, and 95.30% for GAPDH. Ampli-
¢cations were carried out in the GeneAmp SDS 5700 (Applied
Biosystems). The amount of DC-CK1, normalized to GAPDH
and relative to normal skin, was calculated as 2DDCT with
DDCT ¼ (CT chemokine, sampleCT GAPDH, sample)(CT chemokine,
skinCT GAPDH, skin). CT is de¢ned as the cycle when the
threshold level of £uorescence is reached.
Tcell receptor (TCR) clonotype mapping by DGGE DGGE
analysis used for clonotype mapping of the humanTCR bvariable
(BV) regions 1^24 has been described previously (thor Straten
et al, 1998). Brie£y, RNA was extracted using the Purescript
Isolation Kit (Gentra Systems, Minneapolis, MN) and synthesis
of cDNA was done with 1^3 mg of total RNA, oligo-dT, and
SuperScript II reverse transcriptase (Invitrogen, Karlsruhe,
Germany). cDNA was ampli¢ed by primers speci¢c for BV
families 1^24 and a constant region primer that contains a 50 bp
GC-rich sequence at the 50 end. DGGE analysis was done in 6%
polyacrylamide gels containing a gradient of urea and formamide
from 20% to 80% separating the amplicons due to their melting
properties, which are based on their nucleotide sequence.
Construction of multimeric peptide/HLA-An0201 com-
plexes A recognition site for enzymatic biotinylation using
biotin protein ligase (BirA) in fusion with the 50 end of the
extracellular domains of HLA-An0201 (residues 1^275) was
expressed in Escherichia coli BL21 (DE3). The recombinant
protein was puri¢ed by size exclusion (Sephadex G25,
Pharmacia, Erlangen, Germany) and ion exchange (mono-Q,
Pharmacia) chromatography from E. coli inclusion bodies
solubilized in 8 M urea. The HLA-An0201 was folded in vitro by
dilution in the presence of the respective peptides, and
subsequently biotinylated as described previously (Altman et al,
1996). After gel ¢ltration on a Sephadex G25 column, the
protein was multimerized with streptavidin £uorescein
isothiocyanate conjugated to dextran molecules (kindly provided
by L. Winther, DAKO, Copenhagen, Denmark) to generate
multivalent HLA^dextran complexes (Andersen et al, 2001b).
Table I. Tcell in¢ltrate at vaccination sites
Percentage of CD8þ T cells reactive to HLA-A2-restricted epitopes ofd
Patient HLA phenotypea Antigenb T cell in¢ltratec MART-1 gp100 Mage-3 Survivin Number of T cell clonese
#1 A1, A2 None Dim 0.5 0 0 9 f
gp100 Brisk 0 12 0 10
Mage-3 Interm. 8
Onkolysate Brisk 6 5 29f
#2 A2 None Dim 2
Mage-3 Interm. 0 10 6
Oncolysate Brisk 4.5 0 n.d.g
#3 A3, B44 Tyrosinase Brisk 25
gp100 Interm. 0 22
#4 A2, A3 Tyrosinase Interm. 0 0 0 17
#5 B44 Mage-3 Brisk 3
#6 A2 Survivin Dim 0 0 0 10 5
aonly the parts of the HLA phenotype relevant for the vaccination are given.
bThe peptide sequence is given in Materials and Methods.
cThe magnitude of the T cell in¢ltrate was graded according to the guidelines suggested by Clark et al (1989) as brisk, intermediate (interm.), and dim.
dThe frequency of reactive T cells was evaluated by counting at least 20 high power ¢elds; blanks indicate that this analysis was not performed for the respective sample.
eRepresented by bands in the DGGE.
fdepicted in Fig 4.
gDue to the lack of material only a limited number of investigations could be performed.
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The HLA-An0201 construct was a kind gift of Dr. Mark M.
Davis (Department of Microbiology and Immunology, Stanford
University, Palo Alto, Ca).
Immunohistochemistry and antibodies Frozen sections were
¢xed in cold acetone for 10 min followed by removal of
endogenous peroxidase with 0.03% H2O2 and blocking of
collagenous elements with 10% bovine serum albumin. Serial
sections were incubated for 30 min with biotinylated antibodies
at predetermined dilutions (usually 20 mg per ml). Subsequently,
the streptavidin^peroxidase complex (DAKO, Hamburg,
Germany) was applied for 30 min, followed by a 15 min
incubation with the chromogen AEC (DAKO). Finally, slides
were counterstained with hematoxylin (DAKO) and mounted
in Aquatex (Merck Eurolab, Darmstadt, Germany). Double
staining was performed as previously described (Schrama et al,
2001b).
The staining procedure for multimeric peptide/MHC
complexes has been described recently (Andersen et al, 2001b).
Brie£y, sections were dried overnight and subsequently ¢xed in
cold acetone for 5 min. All incubation steps were performed in
the dark at room temperature as follows: (i) 45 min of the
primary antibody (1:100 diluted); (ii) Cy3-conjugated goat
antimouse (1:500 diluted; code 115-165-100, Dianova, Hamburg,
Germany) for 45 min; and ¢nally (iii) the multimers for 75 min.
Between each step the slides were washed twice for 10 min in
phosphate-bu¡ered saline/bovine serum albumin 0.1% and then
mounted in Vectashield and observed under a Leica Confocal
Microscope (TCS 4D, Leica, Mannheim, Germany).
All antibodies used [anti-CD3, code A0452 (DAKO); anti-
VB12.1, clone S511; anti-VB14, clone CAS1.1.3 (Hybridomus,
Rhoon, The Netherlands); anti-CD8, clone HIT8a; anti-
CD45RA, clone HI 100; anti-CD62L, clone Dreg-56; anti-
CD83, clone HB15e; anti-PNAd, clone MECA-79 (Pharmingen,
San Diego, CA); anti-TCA-4, code BAF366 (R&D Systems,
Wiesbaden, Germany)] are commercially available.
RESULTS
Presence of mature DC as well as L-selectinþ T cells at
cutaneous injection sites Migration studies demonstrated that
the majority of mature DC remain at the site of cutaneous
injections (Eggert et al, 1999; Lappin et al, 1999). In order to
determine whether DC entrenched in this microenvironment
are nevertheless able to stimulate immune responses, we
analyzed skin biopsies obtained from such vaccination sites by
immunohistochemistry. The vaccination sites were characterized
by in£ammatory signs, i.e., erythema, hyperthermia, and
swelling. As expected, mature CD83þ DC were present
throughout the vaccination sites regardless of whether the cells
were pulsed with antigen or not (Fig 1A, B).
The intended role of DC used in vaccination is to initiate
immune responses, i.e., to present captured antigens to naive T
cells. This occurs in secondary lymphoid tissue as naive T cells
require specialized blood vessels^high endothelial venules
(HEV)^to circulate into tissue. HEV are characterized by
luminal expression of speci¢c homing receptors such as
peripheral lymph node addressin (PNAd). As depicted in
Fig 1(C) the endothelial cells of the blood vessels at the
vaccination sites expressed PNAd. Furthermore, thymus-derived
chemotactic agent 4 (TCA-4) (secondary lymphoid tissue
chemokine, 6Ckine, Exodus-2), which is constitutively
presented on the luminal surface of HEVs (Stein et al, 2000) and
mandatory for leukocyte-function-antigen-1-mediated T cell
adhesion on these vessels, was found to be presented in the
glycocalix of the blood vessels (Fig 1D). Although the staining
intensity for TCA-4 was rather modest compared to that
observed in normal lymph nodes, the degree was similar to that
described in tertiary lymphoid tissues (Schrama et al, 2001b).
Notably, the induction of PNAd and TCA-4 was not dependent
on the nature of the antigen, i.e., peptides, oncolysate, or nothing,
presented by the injected DC.
To scrutinize the status of the vaccination site in¢ltrating T
cells, we performed double stainings with L-Selectin, the ligand
for PNAd, and CD45RA. To this end, we detected L-Selectinþ /
CD45RA^ cells, which are likely to represent antigen-
experienced central memory cells, as well as L-Selectin/
CD45RA coexpressing cells, i.e., presumably naive T cells
(Fig 2A, B). The accrual of these cells is likely to be facilitated
by a localized overexpression of the chemokines DC-CK1 and
SDF-1. The former preferentially attracts naive T cells (Adema
et al, 1997), whereas SDF-1 acts more broadly on lymphocytes
and monocytes. We estimated the expression of these
chemokines by real-time PCR assays using the DDCT method
to calculate their relative amounts within the vaccination sites
compared to normal skin. Figure 3 depicts the relative
overexpression of both chemokines at the vaccination site for up
to 48 h.
Interestingly, the magnitude of the in£ammatory in¢ltrate at
the vaccination site seems to depend on the nature of the
presented antigens: the number of in¢ltrating CD3þ T cells was
found to be larger if oncolysate or a cocktail of peptides was used
to pulse DC compared to empty DC although equal numbers of
DC were injected (Table I, Fig 2C, D). Double staining with
CD3 and CD83 demonstrated the close vicinity of in¢ltrating
T cells and injected dendritic cells (Fig 2E, F).
Oligoclonal TCR repertoire within DC injection sites If
vaccination site in¢ltrating T cells do indeed undergo antigen-
speci¢c expansion in loco, this should result in an oligoclonal
TCR usage as opposed to a nonspeci¢c in£ammation, which
would be characterized by a polyclonal TCR usage. To address
this question we applied RT-PCR/DGGE clonotype mapping,
which allows us to distinguish between clonally expanded and
polyclonal members within each TCR BV family of selected
T cell populations^in this case in£ammatory in¢ltrates at
vaccination sites^without any means of in vitro expansion. In this
denaturing gradient gel a polyclonal TCR usage appears as a
smear, whereas clonally expanded T cells form a distinct band.
Thus, a T cell clone can be detected with a sensitivity of 0.1%
beyond a polyclonal background (thor Straten et al, 1998). This
analysis performed for the BV regions 1^24 revealed clonal
expanded T cells belonging to di¡erent TCR families at
Figure1. Immunohistologic characterization of vaccination sites.
Skin biopsies were obtained from injection sites of either nonpulsed
(A, C, D) or oncolysate-pulsed (B) DC. Sections of these were subjected
to staining with antibodies directed against CD83 (A, B), PNAd (C), or
TCA-4 (D). Magni¢cation: 50 (C) and 200 (all others).
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vaccination sites containing antigen-pulsed DC (Table I and
Fig 4B). In contrast, only a few bands were detected at the
injection sites of nonpulsed DC (Table I, Fig 4A). These
observations indicate that despite the fact that DC injected
intradermally by themselves are able to induce an in£ammatory
in¢ltrate, a relevant clonally restricted increase of T cells depends
on the presentation of antigen.
The exquisite sensitivity of RT-PCR/DGGE clonotype
mapping implies the risk that single T cells within one TCR BV
family may be misinterpreted as an accumulation of T cells of
clonal origin. The presence of adequate numbers of T cells at the
vaccination sites as depicted in Fig 2 and summarized inTable I
already minimized this possibility. Nevertheless, we performed a
series of immunohistochemical analyses using antibodies directed
against individual TCR BV families for which T cell clones were
detected. Representative stainings, i.e., using antibodies to Vb12
and Vb14 to stain the samples for which the clonotype maps
were generated, are given (Fig 4). Vb12 and Vb14 were chosen
because the clonotype map of the former displayed several
clonotypic cells in a polyclonal background, represented by
distinct bands among a polyclonal smear, whereas the latter
family is only composed of two clonotypic T cell populations.
Stainings of vaccination sites containing antigen-pulsed DC
demonstrated the presence of numerous T cells carrying these
respective TCR family members (Fig 4B); thus, this observation
con¢rms the feasibility of the applied approach. In contrast, at the
injection site of nonpulsed DC only single cells expressing
the corresponding TCR families were identi¢ed (Fig 4A).
Therefore, the few bands observed within the clonotype maps
of nonpulsed vaccination sites (Fig 4A) are likely to represent
single T cells.
Melanoma-associated antigens recognizing T cells The
speci¢city of the vaccination site in¢ltrating T cells was
determined by in situ staining with multimeric peptide/HLA
complexes. This analysis demonstrated the presence of T cells at
the vaccination site that were reactive to the peptide epitopes
presented by the injected DC. A representative example is
depicted in Fig 5; oncolysate-pulsed DC contained a/b T cells
reactive towards di¡erent melanoma-associated antigens (MAA),
namely MAGE-3271^279, gp100209^217, and MART26^35. In
contrast, vaccination sites of single-peptide-pulsed DC harbored
only T cells speci¢c towards the pulsed peptide (Table I). The
Figure 2. T cell in¢ltrate at antigen-pulsed and nonpulsed DC vac-
cination sites. Skin biopsies were obtained from vaccination sites of non-
pulsed (A, C, E) or oncolysate-pulsed (B, D, F) DC. Antibodies directed
against CD62L (A, B; open arrowhead) or CD3 (CF) were visualized by a
red color, those directed against CD45RA (A, B) or CD83 (E, F) by a blue
color. Double-positive cells appear purple (black arrows).Magni¢cations: 50
(A, B) and 400 (all others).
Figure 3. Relative overexpression of DC-CK1 and SDF-1 at vacci-
nation sites compared to normal skin. Messenger RNA encoding
DC-CK1, SDF-1, and the housekeeping gene GAPDH expressed within
vaccination sites 48 h after injection of DC and normal skin was measured
by real-time PCR. The relative expression of DC-CK1 (gray) and SDF-1
(dark gray) was calculated by the DDCTmethod with normal skin as calibra-
tor. Samples 1 and 2 were obtained from patient 3 receiving either
gp100209^217 or tyrosinase192^200 peptide pulsed DC; sample 3 was derived
from patient 4 receiving tyrosinase214^222 peptide pulsed DC. The insert
depicts original real-time PCR graphs for DC-CK1 (black) and GAPDH
(gray) ampli¢cation of normal skin (circled lines) and sample 1 (line). Rn re-
presents the level of £uorescence detected, the dotted black line the detec-
tion threshold.
Figure 4. Clonotype maps of vaccination sites. Skin biopsies from in-
jection sites of nonpulsed (A) or oncolysate-pulsed (B) DC were subjected
to clonotype mapping. Within the clonotype maps covering the BV
regions 1^24 each distinct band represents a clonally expanded T cell. To
ensure the feasibility of the applied method, the extent of respective T cell
BV families was evaluated by immunohistochemistry as exempli¢ed
for Vb12 and Vb14. Magni¢cation of immunohistochemistry ¢gures:
100 (A), 200 (B).
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frequency of such speci¢c cells among CD8þ T cells ranged
from 0.5% to 12% depending on the antigens used for pulsing
the DC (Table I). The highest frequencies were observed if DC
were pulsed with only one peptide epitope, whereas the
frequencies for the individual MAA/HLA-An0201 reactive T cells
were substantially lower at injection sites of oncolysate-pulsed
DC. In the latter, MART26^35/HLA-A
n0201 reactive T cells were
detected with the highest frequency. Notably, no correlation
between the T cell in¢ltrate at the vaccination site or frequency
of tumor-antigen-speci¢c T cells within this in¢ltrate and
clinical responses could be observed. Vaccination-induced
clinical responses, however, were limited to disease stabilization
and no objective tumor regression was observed.
Vaccination-site-speci¢c T cell clones To test the hypothesis
whether the observed aggregation of T cells of clonal origin at
the vaccination site was merely due to the recruitment from
peripheral blood, we analyzed peripheral blood obtained prior
to vaccination for the presence of MAA-speci¢c T cell clones. To
this end, peptide/MHC class I-coated magnetic beads were used
(Schrama et al, 2001a).We assumed that if the accrual of antigen-
speci¢cTcells at the vaccination site within 24 h is only re£ecting
a selective recruitment, such cells should be present in the
peripheral blood to a degree detectable by this approach. Thus,
we analyzed (i) peripheral blood lymphocytes obtained from
blood drawn 1 d prior to vaccination, (ii) MAA/HLA-An0201
reactive T cells isolated from these peripheral blood
lymphocytes, and (iii) skin biopsies taken from vaccination sites.
As exempli¢ed for gp100209^217 reactive T cells in Fig 6, we
observed several identical T cell clones in the whole peripheral
blood lymphocyte population and the MAA/HLA-An0201
reactive T cell fraction, which, however, never matched the T cell
clones detected at the vaccination site (Fig 6).
DISCUSSION
The use of DC to present tumor-associated antigens and thereby
to generate tumor-speci¢c immunity is a widely applied immu-
notherapeutic approach to ¢ght neoplastic diseases (Timmerman
and Levy, 1999). Although promising clinical results have been
reported (Nestle et al, 1998; Schuler-Thurner et al, 2000; Andersen
et al, 2001a), a major question still to be resolved is the appropriate
application route of these in vitro matured, antigen-pulsed DC. In
this regard, recent ¢ndings demonstrated that only a small frac-
tion of intradermally injected DC migrate to the draining lymph
node and the majority of the cells remains at the injection site
(Morse et al, 1999). This observation prompted us to test if the
DC remaining at the injection site are capable of eliciting an im-
mune response in loco. Indeed, we detected aggregations of T cells
of clonal origin, speci¢cally recognizing the antigens used for
vaccination at these sites.
Detailed characterization of the vaccination sites demonstrated
that mature DC in£ict changes to the microenvironment in
which they are placed that enable the recruitment of naive and
antigen-experienced central memory T cells. This notion is sub-
stantiated by previous reports concluding that DC (i) are involved
in the induction and maintenance of HEV (reviewed in Girard
and Springer, 1995), (ii) serve as nucleation sites to organize lym-
phoid structures in in£amed tissue and thereby sustain chronic
in£ammatory reactions (Sallusto and Lanzavecchia, 1999), and
(iii) express chemokines that recruit various types of leukocytes
(Adema et al, 1997; Hashimoto et al, 2000). Hence, it seems con-
ceivable that in vitro matured DC present at the vaccination site
produce chemokines, which by themselves or through attraction
of other cells change the microenvironment towards a tertiary
lymphoid tissue.This e¡ect is probably not dependent on an anti-
gen load of the DC as nonpulsed DC were equally able to induce
such changes (Fig 1C, D). The speci¢city and the magnitude of
the in¢ltrating T cells, however, were dependent on the presence
of antigen.
Although the presence of small T cell clusters of the same spe-
ci¢city already 24 h after injection suggest the in loco proliferation
of speci¢c T cells, no de¢nite proof can be obtained in humans.
Recent reports on the kinetics of Tcell responses indicate that the
Figure 5. Speci¢city of in¢ltrating T cells. Sections of skin biopsies,
obtained 24 h after cutaneous injection of oncolysate-pulsed DC, were sub-
jected to double staining with anti-TCRVb12 antibodies (red) and MAA/
HLA-An0201 multimers (green). The MAA-derived peptides used for gen-
eration of multimers are MART26^35 (upper part), gp100209^217 (middle part),
or MAGE-3271^279 peptides (lower part). The images at the far right repre-
sent the digital overlay of the ¢rst two rows. Double positive cells appear
yellow.
Figure 6. TCR repertoire usage at vaccination sites di¡ers from that
of antigen-reactive cells circulating in peripheral blood. Compara-
tive clonotype mapping for selected TCR BV families of (1) bulk periph-
eral blood lymphocytes and (2) gp100209^217/HLA-A
n0201 reactive T cells,
both obtained 24 h prior to vaccination with gp100209^217 peptide pulsed
DC, or (3) the respective vaccination site after 24 h. Identical clones are
retained at the same position in the gel.
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division rates of CD8þ T cells range between 8 and 24 h during
a primary viral immune response (Murali-Krishna et al, 1998) and
that naive T cells become committed after as little as 2 h of
exposure to antigen-presenting cells (van Stipdonk et al, 2001).
The rapid activation at vaccination sites can be further explained
by the serial encounter model for T cell activation (Gunzer et al,
2000) stating that naiveTcells have to accumulate multiple short-
lived antigen-speci¢c signals from several encounters to the same
or di¡erent DC in order to become activated; both contact time
and contact frequency determine whether a T cell becomes acti-
vated. At vaccination sites the frequency of antigen-speci¢c en-
counters should be rather favorable due to the high number of
DC pulsed with a limited number of antigens. Thus, even for
naive T cells a rapid proliferative response is feasible.
In adjuvant and therapeutic settings, an immune response re-
stricted to the vaccination sites would not be su⁄cient to control
the tumor, i.e., minimal residual or manifest disease, respectively.
Therefore, we and others have searched for and indeed detected
systemic responses in the peripheral blood of vaccinated melano-
ma patients either by direct staining of antigen-speci¢c T cells
using tetrameric peptide/MHC class I complexes (Thurner et al,
1999; Pittet et al, 2001) or by measuring antigen-speci¢c cytokine
production, i.e., ELISPOTanalysis or intracellular cytokine stain-
ing. For two of the patients used for the present analysis the de-
tailed characteristics of their antigen-speci¢c T cell response
before, during, and after vaccination are available (Andersen
et al, 2001a). Notably, the origin of these T cell responses cannot
be attributed to local reactions at the vaccination site, DC
migrating to secondary lymphoid tissue, the boost of preexisting
antigen-experienced cells, or a combination of all these possibili-
ties. As the dissection of this problem is not practicable in hu-
mans, current experiments in murine tumor models address
these questions.
In summary, our results demonstrate that the injection of in
vitro matured and antigen-pulsed DC sustains a speci¢c immune
response at the vaccination site. Physiologically, the encounter of
antigen-presenting cells andTcells occurs in secondary lymphatic
tissues such as lymph nodes. DC-based vaccination brings about a
nonphysiologic situation, however, placing mature DC into the
cutaneous compartment, where this potent cell population in-
£icts changes on the microenvironment that are likely to enable
the recruitment and^probably^expansion of T cells reactive
against the desired antigens.
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